Multisystem Inflammatory Syndrome in Children Admitted to a Tertiary Pediatric Intensive Care Unit
- PMID: 36742251
- PMCID: PMC9894696
- DOI: 10.1055/s-0041-1733943
Multisystem Inflammatory Syndrome in Children Admitted to a Tertiary Pediatric Intensive Care Unit
Abstract
Background Multisystem inflammatory syndrome in children (MIS-C) is characterized by persistent fever, abdominal pain, vomiting, diarrhea, rash, conjunctivitis, headaches, and mucocutaneous manifestations and it can cause circulatory dysfunction, resulting in hypotension, shock, and end-organ injury in the heart and other organs and possibly death. In this study, we aimed to analyze the clinical spectrum, treatment options and outcomes of children with MIS-C who were admitted to our pediatric intensive care (PICU). Materials and Methods Clinical and laboratory findings and treatment of the patients admitted to the PICU with MIS-C between April 2020 and January 2021 were recorded, and their outcomes were evaluated. Results Nineteen patients with a median age of 12.5 years (interquartile range (IQR): 5.8-14.0 years) were admitted. Eleven (57.8%) were males. The most frequent clinical and laboratory features were fever (100%), abdominal pain (94.7%), rash (63.1%), headache (68.4%), diarrhea (47.3%), seizure (10.5%), cardiac dysfunction (52.6%), acute kidney injury (26.3%), lymphopenia (84.2%), and thrombocytopenia (36.8%). However, 8 patients needed mechanical respiratory support, 11 patients needed inotropes, 2 patients needed plasma exchange, and 1 patient needed continuous renal replacement therapy. All patients received corticosteroids, 17 patients (89.2%) received intravenous immunoglobulin, 2 patients received anakinra, 10 patients received acetylsalicylic acid, and 6 patients received enoxaparin. Median PICU length of stay was 3 days (IQR: 2-5) and only one patient died. Conclusion In conclusion, MIS-C may present with a variety of clinical manifestations, and it can lead to life-threatening critical illness. Most children need intensive care and the response to immunomodulation is usually favorable.
Keywords: COVID-19; children; multisystem inflammatory syndrome in children; pediatric intensive care.
Thieme. All rights reserved.
Conflict of interest statement
Conflict of Interest None declared.
Figures
References
-
- Blumfield E, Levin T L, Kurian J, Lee E Y, Liszewski M C. Imaging findings in multisystem inflammatory syndrome in children (MIS-C) associated with coronavirus disease (COVID-19) Am J Roentgenol. 2021;216(02):507–517. - PubMed
-
- Spanish Pediatric Intensive Care Society working group on SARS-CoV-2 infection . García-Salido A, de Carlos Vicente J C, Belda Hofheinz S. Severe manifestations of SARS-CoV-2 in children and adolescents: from COVID-19 pneumonia to multisystem inflammatory syndrome: a multicentre study in pediatric intensive care units in Spain. Crit Care. 2020;24(01):666. - PMC - PubMed
LinkOut - more resources
Full Text Sources
Miscellaneous
